

Session Title: 155 - RWE Methods and Applications

Innovations in Automated Survival Curve Selection and Reporting of Survival Analyses through Generative AI

Authors: Yunchou Wu (Estima Scientific), Sven Klijn (BMS), Siguroli Teitsson (BMS), Bill Malcolm (BMS), Cheryl Jones (Estima Scientific), Will Rawlinson (Estima Scientific)

Affiliations:

ISPOR EU, Barcelona, Spain

17th-20th November 2024

Session: P24, Monday 18th November 5pm

What is the problem we want to solve?

- **Survival analysis** is a crucial step involved in cost-effectiveness modelling (CEM), particularly in disease areas such as oncology
- Experts often spend significant amounts of time considering both survival analysis outputs and external data to ensure an appropriate curve is selected
- Experts must provide clear rationale and justifications for the curve selected
- The selection of a curve is a highly influential, and often sensitive, driver of CEM results

What we require of an automated system?

01



Automation to significantly reduce time spent on curve selection


02



Require reasons and justifications behind the curves that have been selected

Why are LLMs suitable for automating survival curve selection?

- Vision capabilities of LLMs have significantly improved → LLMs can interpret graphs
- Reasoning capabilities of LLMs → LLM can provide reasons for the assessments and decisions made



Study Objective

To leverage LLMs and explore automation of survival curve selection following published best practice guidelines⁵

LLMs were used to:



Assess data generated by a survival analysis and relevant external data



Recommend an appropriate extrapolation curve



Provide rationale and justifications for all decisions made

Two Case Studies in Oncology


Two survival reports previously accepted by NICE:

- 01 NICE TA817:** Survival analysis for patients treated with Nivolumab vs. Placebo for resectable urothelial cancer (PD-L1 $\geq 1\%$) [CheckMate 274]
 - **External data:** Published Kaplan Meier plot for placebo in similar patient population

- 02 NICE TA417:** Nivolumab vs. Everolimus for previously treated advanced Renal Cell Carcinoma (RCC) [CheckMate 025]
 - **External data:** Clinical expert opinion - landmark survival estimates at year 5


Methods

Automated process for curve selection and reporting





Structure of prompts to guide the LLM



Proportional Hazards

Log Cumulative Hazard Plot
Schoenfeld Residual's Plot
Grambsch-Therneau Test

Overall Decision

PH Holds
Dependent Models

PH does not hold
Independent Models

PH Unclear
Both

Goodness-of-fit

AIC/BIC
Landmark Survival Probabilities
Visual Fit of Extrapolations (graph)
External Data


Overall Decision - Select Curve

Prompt Development



Prompting techniques used were:

- Few-shots - Provide the LLM with a few relevant examples to guide its generation
- Chain-of-thought - Break down a complex problem into a sequence of logical steps for the LLM to follow



Prompts were designed to be generalizable (i.e., apply the same prompts to both case studies)



Claude 3.5 Sonnet [version 1] was used to generate the results

Assessing Accuracy of Responses



Assess the rationales and/or justifications provided by the LLM for decisions made against the expert opinion of 3 health economists

- 01** Interpretation of survival analysis outputs
- 02** Overall decisions made, taking account of external data

Results

Appropriate justifications provided by LLM


Assess the justifications for decisions made by the LLM against the expert opinion of 3 health economists

Trial	Statement Type	Number of Statements by LLM	Number of Appropriate Statements
NICE TA817	Interpretation of survival data	28	28 (100.0%)
	Justifications for overall decisions	14	14 (100.0%)
NICE TA417	Interpretation of survival data	28	27 (96.4%)
	Justifications for overall decisions	14	14 (100.0%)

Limitations of Vision Capabilities

- LLM stated the dashed 95% CI crossed the red-line
- Did not affect the overall interpretation and decision related to the plot
- Signals potential vision issues

Schoenfeld Residual Plot



Discussion

Automated Curve Selection is Possible



Our research suggests LLMs are able to:

- Interpret evidence generated by survival analysis
- Produce sensible rationales for its decisions
- Use survival analysis outputs and external evidence to inform appropriate curve selections

Further Research



- 01** Concerns about vision capabilities of Claude 3.5 Sonnet [version 1],⁶ may impact reliability
 - Claude 3.5 Sonnet [version 2] was released with enhanced vision capabilities
 - Send data and images to the LLM
- 02** For the automated process to be most effective, it must also accommodate complex models, including Splines and Cure models
- 03** Incorporate a “human-in-the-loop” approach to add further context (e.g. clinical)

Conclusion

- Our research shows LLMs can be leveraged to automate the assessment of survival analysis outputs and select a curve to predict long-term outcomes for use in cost-effectiveness modelling
- LLMs can provide an additional view-point which may be valuable to experts selecting a curve
- Ultimately an automated survival analysis process can speed-up curve selection process and allowing patients faster access to life-saving treatments

Declaration of Interests



This study was supported by Bristol Myers Squibb

Wu Y, Jones C, Rawlinson W:

None

Klijn S, Teitsson S, Malcolm W:

Employees of Bristol Myers Squibb